Company intelligence / Profile preview

Akinion Pharmaceuticals AB

Solna, Stockholm Region, Swedenorpha.net ↗

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

Developed signal transduction inhibitors targeting AML with focus on FLT3 and c-Kit. Lead program AKN-028 was in clinical trials but has been discontinued.

Therapeutic areas: Oncology
Modalities: Small molecule kinase inhibitors (notably FLT3 and c-Kit inhibitors)
Industry: Biotech

Drug pipeline

3 assets

quizartinib

Phase 3

Indications: Acute myeloid leukemia

2 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed beyond shareholder relationships.

Beyond the preview

Go deeper on Akinion Pharmaceuticals AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akinion Pharmaceuticals AB.

Explore the full profile